- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07212751
- Original Trial
Coronary CT Angiogram - Prognostic Value of Adverse Plaque Features in Guiding Treatment (CT-PLAQUE) (CT-PLAQUE)
The study aims at determining if the presence of adverse plaque features identified from the CT angiogram can help determine prognosis and guide treatment options.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
-
Hong Kong, Hong Kong
- The University of Hong Kong
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
28000
Description
Inclusion Criteria:
- Patient who is ≥ 18 years old presented with chest pain and has undergone CTA between 01-Jan-2012 and 31-Dec-2022 before treatment
- If multiple CTAs are taken, the most updated one before treatment commencement will be chosen.
Exclusion Criteria:
- Patient who did not undergo cardiac CT scan due to inability to undergo cardiac CT scanning, kidney failure (serum creatinine >250 μmol/L or estimated glomerular filtration rate <30 mL/min), major allergy to contrast.
Study Plan
How is the study designed?
Design Details
- Observational Models: CASE_CROSSOVER
- Time Perspectives: CROSS_SECTIONAL
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Patient who is ≥ 18 years old presented with chest pain and has undergone CTA before treatment
|
Patient who is ≥ 18 years old presented with chest pain and has undergone CTA between 01-Jan-2012 and 31-Dec-2022 before treatment - If multiple CTAs are taken, the most updated one before treatment commencement will be chosen. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death and all-cause death
Time Frame: 5 years after CTCA examinations
|
5 years after CTCA examinations
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Total plaque (mm³) to predict cardiac events
Time Frame: 5 years after CTCA examinations
|
5 years after CTCA examinations
|
|
Calcified plaque (mm³) to predict cardiac events
Time Frame: 5 years after CTCA examinations
|
5 years after CTCA examinations
|
|
Non-calcified plaque (mm³) to predict cardiac events
Time Frame: 5 years after CTCA examinations
|
5 years after CTCA examinations
|
|
CT-FFR to predict cardiac events
Time Frame: 5 years after CTCA examinations
|
5 years after CTCA examinations
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Pathological Conditions, Anatomical
- Heart Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Myocardial Ischemia
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Stroke
- Coronary Artery Disease
- Plaque, Amyloid
- Chest Pain
Other Study ID Numbers
- UW20-057
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.